ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Aug 10th, 2022 - We report an 80-year-old male developing linear IgA bullous dermatosis (LAD) in the setting of angioimmunoblastic T-cell lymphoma (AITL). This phenomenon is rare, as only three cases have been described in the literature. The pathophysiologic proc...

Aug 9th, 2022 - Hematopoietic cells are instrumental in generating and propagating protective inflammatory responses to infection or injury. However, excessive inflammation contributes to many diseases of the blood, bone marrow, and lymphatic system. We review th...

Aug 4th, 2022 - Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes development of T follicular helper-l...

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Aug 2nd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Aug 2nd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Aug 1st, 2022 - Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until any condition for treatment discontinuation has been met. Patients will be enrolled into one of four cohorts: Peripheral T-Cell Lymphoma, not otherwise spe...

Jul 19th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

May 25th, 2022 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...

Mar 29th, 2022 - Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma arising from follicular T-helper cells that predominantly affects older adults and carries a 5-year overall survival rate of 32%. 1 Notably, as many as 50% of AITL patients.

Apr 2nd, 2021 - Transcript: Neha Mehta-Shah, MD: Dr Chadi Nabhan at ASH [the American Society of Hematology Annual Meeting & Exposition] this year presented a retrospective review of about 200 patients who have peripheral T-cell lymphoma across a number of su...

Apr 2nd, 2021 - Transcript: Neha Mehta-Shah, MD: Peripheral T-cell lymphomas are a relatively uncommon subset of non-Hodgkin lymphomas. They make up about 10% of all non-Hodgkin lymphomas. There are about 7000 cases per year. About half of those are the syste...

Jan 5th, 2021 - Key clinical point: Researchers used flow cytometry and genomic assessment to identify a shared DNMT3A mutation in a rare case of angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome. Major finding: DNMT3A N612Rfs*36 was identified as t.

Dec 20th, 2020 - The anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AIT...